A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Patients With Egfr And C-met Expressing Advanced Solid Malignancies
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Adequate organ and bone marrow function (in the absence of blood transfusion or growth factor support within 14 or 21 days, respectively, prior to enrollment)
    2. Measurable disease as defined by at least 1 lesion. The doctors will use a CT or MRI scan to see if there is at least one part of the cancer that is at least 10 millimeters long. If the cancer is in your lymph nodes, the short axis of the lymph node has to be at least 15 millimeters long

You may not be eligible for this study if the following are true:

    1. Patients with cancer-related spinal cord compression or a history of leptomeningeal carcinomatosis
    2. Unresolved toxicities from prior therapy or uncontrolled illness within the last 12 months
    3. Cardiovscular disorder which includes arrhythmia, uncontrolled hypertension, etc.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.